Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2024BiomedicinesOpen Access

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

DFDanaë Martinez FloresDADilara AkhoundovaKSKatja Seipel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Flores et al. (2024) studied this question.

synapsesocial.com/papers/68e5fb84b6db64358758fc60https://doi.org/10.3390/biomedicines12071616
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial2010 · 658 citations
  2. 2Hematopoietic Stem-Cell Transplantation2006 · 2,527 citations
  3. 3Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial2018 · 368 citations
  4. 4Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study2019 · 113 citations